Fig. 2.

Antitumor activity of DZ-2384, docetaxel, and paclitaxel in metastatic lung and brain triple-negative breast cancer (TNBC) models. (a–d) Mice bearing MDA-MB-231-LM2 lung metastases were treated biweekly for 2 weeks with DZ-2384 (a, b) or docetaxel (c, d) biweekly for 2 weeks (treatment days indicated by arrows). (e, f) Mice bearing intracranially transplanted MDA-MB-231-BrM2 cells were treated biweekly for 2 weeks with DZ-2384 or paclitaxel (treatment days indicated by arrows). (a, c, e) Mean bioluminescence signal±SEM measured weekly. A tumor-free animal was imaged to represent the background signal. (b, d, f) are Kaplan–Meier curves depicting survival. Statistical differences with vehicle control are indicated to the left of the legend and were determined by Student’s t-test for bioluminescence and log-rank (Mantel–Cox) test for survival curves. Asterisks on the left of the legend represent differences with vehicle control, on the right differences between groups. *P<0.05, **P<0.005, ***P<0.0001.